Industry-Sponsored Ghostwriting in Clinical Trial Reporting: A Case Study
McHenry, Leemon B.
Jureidini, Jon N.
Accountability in Research 2008 July-September; 15(3): 152-167
In this case study from litigation, we show how ghostwriting of clinical trial results can contribute to the manipulation of data to favor the study medication. Study 329 for paroxetine pediatric use was negative for efficacy and positive for harm. Yet the ghostwritten publication from this study concluded that paroxetine provided evidence of efficacy and safety and continues to be influential. Despite the role of named authors in revisions of the manuscript, the sponsor company remained in control of the message.
Showing items related by title, author, creator and subject.
Physician Remuneration in Industry-Sponsored Clinical Trials: The Case for Standardized Clinical Trial Budgets Ferris, Lorraine E.; Naylor, C. David (2004-10-12)
Pyke, Stephen; Julious, Steven A; Day, Simon; O'Kelly, Michael; Todd, Susan; Matcham, James; Seldrup, Jorgen (2011-01)Concerns about potentially misleading reporting of pharmaceutical industry research have surfaced many times. The potential for duality (and thereby conflict) of interest is only too clear when you consider the sums of ...
Proposed Best Practice for Statisticians in the Reporting and Publication of Pharmaceutical Industry-Sponsored Clinical Trials Matcham, James; Julious, Steven; Pyke, Stephen; O'Kelly, Michael; Todd, Susan; Seldrup, Jorgen; Day, Simon (2011-01)In this paper we set out what we consider to be a set of best practices for statisticians in the reporting of pharmaceutical industry-sponsored clinical trials. We make eight recommendations covering: author responsibilities ...